Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Trastuzumab Pamirtecan (BNT323/DB-1303): A Comprehensive Clinical and Scientific Monograph on a Next-Generation HER2-Targeted Antibody-Drug Conjugate
Executive Summary
Trastuzumab pamirtecan, identified by the development codes BNT323 and DB-1303, represents a significant advancement in the field of targeted oncology therapeutics.[1] It is a third-generation antibody-drug conjugate (ADC) meticulously engineered to target the Human Epidermal Growth Factor Receptor 2 (HER2), a well-validated oncogenic driver in a multitude of solid tumors. Developed through a strategic global partnership between BioNTech and Duality Biologics, this agent is built upon Duality's proprietary Duality Immune Toxin Antibody Conjugates (DITAC) platform, which is designed to optimize the therapeutic index of ADCs.[3] The molecular architecture of trastuzumab pamirtecan comprises three essential components: the proven HER2-targeting monoclonal antibody, trastuzumab; a highly potent cytotoxic payload, pamirtecan, which functions as a topoisomerase-1 inhibitor; and a sophisticated, cleavable linker system designed for tumor-selective payload release.[1]
The clinical development of trastuzumab pamirtecan has been marked by a landmark achievement in the pivotal Phase 3 DYNASTY-Breast01 trial (NCT06265428). In this head-to-head study, trastuzumab pamirtecan demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to the established second-line standard of care, ado-trastuzumab emtansine (T-DM1; Kadcyla), in patients with HER2-positive unresectable or metastatic breast cancer.[1] This positive result not only validates the DITAC platform in a late-stage setting but also positions trastuzumab pamirtecan as a formidable new therapeutic option for a patient population with significant unmet needs.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/02/14 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.